Compare Eli Lilly And Co (LLY) vs Vanguard International High Dividend Yield ETF (VYMI) Price & Performance

Eli Lilly (LLY) trades at $1,150.86, down 2.39% on the day, with a bullish technical signal from moving averages and strong fundamental performance. The company reported robust earnings beats in recent quarters, with Q1 2026 EPS of $8.55 exceeding expectations by 23%. Revenue surged to $65.18 billion in 2025, driving a net income margin of 34.99%. Recent news highlights LLY's $2.8 billion acquisition of AtaiBeckley to expand its neuroscience pipeline, signaling strategic growth in mental health treatments.

Outlook remains positive with analyst consensus price target of $1,380 implying 20% upside, supported by 73% buy ratings. Key risks include high valuation multiples (P/E 41.89) and rising debt levels, though operating cash flow growth to $16.81 billion in 2025 provides financial flexibility. Investors should monitor Q2 2026 earnings on August 5 for continued execution on weight-loss drug demand and integration of recent acquisitions.

VYMI trades at $100.23, down 0.65% on the day, with a bullish technical signal driven by moving averages and strong trend momentum (ADX 6-day at 60.71). The ETF offers a forward dividend of $1.26 payable June 23, 2026. Recent news highlights its role in diversifying away from U.S. tech, with Vanguard research suggesting international stocks may outperform over the next decade.

Outlook remains positive given its low 0.07% expense ratio, high dividend yield, and diversification benefits. Risks include currency fluctuations and global economic volatility. Analyst sentiment is favorable, emphasizing sustainable dividends and attractive valuations relative to U.S. markets.